SUNRISE, Fla., July 30 /PRNewswire-FirstCall/ -- Bioheart, Inc., (Nasdaq: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, announced the adoption of the following resolutions during today's Annual Shareholders Meeting:
-- Shareholders approved the election of eight directors to serve until the annual meeting of shareholders in 2009 or until their successors are duly elected and qualified. The elected directors are: Howard J. Leonhardt; Samuel S. Ahn, M.D., MBA; Bruce C. Carson; Peggy A. Farley; David J. Gury; William P. Murphy, Jr., M.D.; Richard T. Spencer III; and Mike Tomas.
-- Shareholders approved and ratified the selection of Grant Thornton LLP as Bioheart's independent registered public accounting firm for the fiscal year ending December 31, 2008.
-- Shareholders approved an amendment to the Corporation's Articles of Incorporation to increase the number of authorized shares of the common stock of the Company from 50 million shares to 75 million shares.
-- Shareholders approved the establishment of the Bioheart Omnibus Equity Compensation Plan.
"The past year has been a period of enormous progress for Bioheart, both in our clinical program and our business development," said Howard J. Leonhardt, chairman and chief executive officer of Bioheart, Inc. "We believe we represent a great hope for the more than 23 million patients suffering from heart failure worldwide."
In his comments to shareholders, Leonhardt noted a number of previously
announced business and clinical highlights. In addition, Leonhardt
announced the signing of a non-binding letter of intent to acquire
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved